MiMedx® History


Sales Team Attends One of the Company’s Education and Development Sessions

MiMedx Group, Inc. was incorporated on February 28, 2008. Its initial assets consisted of our HydroFix® and CollaFixTM technology platforms.

On January 5, 2011, the company acquired all of the outstanding equity interests in Surgical Biologics, LLC, and subsequently consolidated the corporate offices and operating facilities in Kennesaw, Georgia. This strategic acquisition brought together amnion tissue processing technology with MiMedx®'s experienced management team and extensive distribution network in order to position the company for market opportunities across multiple areas of medicine.After nearly two decades of human tissue experience, the Surgical Biologics founders had the vision to apply modern proprietary processing techniques to placental tissue to create unique ophthalmic, spinal, orthopedic, and dental implants.

At the time of the acquisition, Surgical Biologics distributed tissue in several different membrane sub-segments, such as ocular, dental, and spine. Early 2011, MiMedx® launched AmnioFix® for applications in spinal procedures. AmnioFix® is used as a barrier membrane that reduces scar tissue formation between the dura and soft tissue. During 2011, the company launched EpiFix®nationwide. EpiFix® is an allograft specifically processed for acute and chronic wounds. The company further expanded its amnion product offering in 2011 with the introduction of AmnioFix® Wrap for both nerve and tendon protection applications. 

 

Management

MiMedx® has built a management team with highly experienced healthcare executives with track records of leading large healthcare organizations in generating growth, producing profitability, and increasing shareholder value. Our management team draws on guidance from an insightful board of directors and medical advisory board. Collectively, they are committed to achieving success, accomplishing our corporate goals and growing the company. The management team at MiMedx® includes:-

 

Parker H. "Pete" Petit | Chairman of the Board and Chief Executive Officer

Mr. Petit joined MiMedx Group in February 2009 as the Company’s Chairman and Chief Executive Officer. A visionary healthcare executive, Mr. Petit has a history of developing companies from their emerging stages and leading them to maturity and significant stature in their respective markets.
 

In 1970, Mr. Petit founded Healthdyne, an international healthcare company that manufactured high technology healthcare devices, provided healthcare information systems and technology, and provided healthcare services and disease management. The Healthdyne related companies grew to annual revenues in excess of $1 billion.  In order to increase shareholder values, Healthdyne was split into several publicly traded companies through public offerings and spinouts to shareholders.  Subsequently, the home infusion therapy subsidiary was sold to W. R. Grace Corporation.  In 1995, Healthdyne Maternity Management was merged with Tokos Medical to form Matria Healthcare.  At that point, Mr. Petit relinquished the CEO role and remained Chairman of the Board of all the companies.  In 1997, Healthdyne Technologies was merged with Respironics. Mr. Petit resumed the duties of President and CEO of Matria Healthcare in 2000.  In 2001, Healthcare.com, which was formerly Healthdyne Information Enterprises, merged with XCare.net Corporation to form Quovadx. Through Mr. Petit’s vision and leadership, Matria Healthcare transitioned into the industry’s only fully integrated health, productivity and disease management care continuum providing employer and health plan clients access to wellness programs, nurse triage services, decision support programs, disease management programs for chronic diseases, case management programs for acute and catastrophic conditions and unparalleled health data integration and informatics. Matria Healthcare was sold to Inverness Medical Innovations in May of 2008 in a transaction valued at over $1.2 billion. 
 

Mr. Petit served on the Board of Directors of Atlantic Southeast Airlines for 16 years until it was acquired by Delta Airlines, and Norrell Corporation, which was acquired by Spherion Corporation.  He currently serves on the Board of Trustees of the National Health Museum and is a member of the Board of Directors of Intelligent Systems Corporation. Mr. Petit currently serves as President of The Petit Group, an Investment Management Organization. Mr. Petit is a member of the Board of Directors of the Georgia Research Alliance, which is chartered by the state of Georgia to promote high technology and scientific development in the state, and he is a 1994 inductee into the Technology Hall of Fame of Georgia. 
 

Mr. Petit funded a professorial chair for “Engineering in Medicine” at Georgia Tech in 1986.  In 1995, he endowed the Petit Institute for Bioengineering and Biosciences at Georgia Tech.  In 2001, he helped fund the biotechnology building at Georgia Tech which has his name, and in 2004, the Science Center building at Georgia State University which also has his name. 
 

In 2007, he was inducted into the Georgia State Business School Hall of Fame.  In October of 2011, Mr. Petit was inducted into the National Academy of Engineering. Mr. Petit received his bachelor’s degree in Mechanical Engineering and Master of Science degree in Engineering Mechanics from Georgia Tech.  He received his MBA degree in Finance from Georgia State University in 1973.

 

William C. Taylor | President and Chief Operating Officer

Mr. Taylor joined MiMedx Group in June 2009 as a consultant and in September 2009, he was named President and Chief Operating OfficerHe was appointed to the MiMedx Board of Directors in October 2011.  Mr. Taylor is an operating executive with over 25 years’ experience leading fast growth medical device, design and manufacturing companies.
 

Prior to joining MiMedx, Mr. Taylor was the Chief Executive Officer of Facet Technologies, LLC, the world-wide leader in microsampling devices, which were predominately used in diabetes care. Prior to being acquired by a private equity company, Facet was a wholly-owned subsidiary of Matria Healthcare, Inc. From 1994 through 1998, through the leadership of Mr. Taylor and the rest of the team, Facet grew from $14 million to nearly $40 million in revenue. Matria acquired Facet in 1999, and under Mr. Taylor’s leadership, Facet grew to be the global leader in microsampling devices with over a 50% market share and in excess of $85 million in revenue. 
 

During his 14 year career at Facet, he held various management positions, beginning with the Company’s head of R&D, QA & Regulatory Affairs and progressing through general management and ultimately, Chief Executive Officer.
 

With Mr. Taylor as President and COO, MiMedx has put together an infrastructure that is more than capable of generating and serving the prolific demand for its products. Through Mr. Taylor’s operating expertise and the Company’s acquisition of exceptional talent, Mr. Taylor has positioned MiMedx in the critical areas of medical affairs, scientific research, product development, sales & marketing, regulatory affairs, engineering and operations to flawlessly perform through a rapid pace of year-over-year new product development and exponential sales growth.
 

A graduate of Purdue University, Mr. Taylor holds a Bachelor of Science degree in Mechanical Engineering and is co-inventor on eight patents. Mr. Taylor also serves on the MiMedx Group Board of Directors. In 2011, Mr. Taylor was appointed and continues to serve as a member of the Advisory Board of the Georgia Tech Institute for Bioengineering and Bioscience. 

Michael J. Senken | Chief Financial Officer

Mr. Senken has served as Chief Financial Officer of MiMedx since joining the Company in January 2010. Mr. Senken brings to MiMedx over 30 years of financial and operational leadership experience in high growth technology based manufacturing and services companies in large global publicly traded companies, as well as small startup companies. Mr. Senken has extensive experience building financial systems and processes to support rapid growth in lean manufacturing organizations. He also has significant experience in mergers, acquisitions, divestitures and raising capital, strategic planning, Sarbanes Oxley compliance, business controls, business process improvement, and complex financial reporting systems.
 

Mr. Senken’s corporate experience prior to MiMedx includes senior level finance and general management positions at global leader Philips Electronics, in addition to Chief Financial Officer experience with a healthcare services startup organization and a market leading transportations services organization.
 

Immediately before joining MiMedx, Mr. Senken was Vice President and Chief Financial Officer of Park-N-Fly, Inc., the leader in the off-airport parking and on-line reservation systems market with over 160 retail locations. He served with Park-N-Fly from 2007 to 2009. From 2005 to 2007, Mr. Senken was Vice President and Chief Financial Officer of Patient Portal Technologies, a startup healthcare software and services company providing communications, logistics and entertainment services to hospital patients and staff. During 2005, Mr. Senken was a consultant for JC Jones LLC, providing Sarbanes Oxley compliance expertise to clients, including a $2B automobile parts manufacturing company.
 

From 1980 to 2004, Mr. Senken held various financial management positions with the Phillips Consumer Electronics organization, last serving from 2002 to 2004 as Senior Vice President & General Manager-Broadband Consumer Lifestyle, with responsibility for the strategy and business development of the Company’s product offerings in the emerging broadband connected consumer products sector of the industry. Prior thereto, he served Phillips from 1983 to 2002 in the capacity of Senior Vice President and General Manager of Philips Broadband Networks where he had full P&L responsibility with sales, manufacturing and product development locations in the U.S., Europe and Asia. He also served Phillips Broadband Networks as its Vice President and Chief Financial Officer from 1986 to 1996 and as its Controller from 1983 to 1986. Mr. Senken joined the Phillips organization in 1980 as an auditor for Philips Electronics North America.
 

Mr. Senken earned a B.A. in Accounting from Saint John’s University in 1980 and passed the CPA exam in the state of New York. He is a graduate of the Philips Global Leadership Development Program and has earned the Six Sigma Green Belt certification. 

 

Roberta McCaw | General Counsel and Secretary

Ms. McCaw currently serves in the capacity of General Counsel. From January 2009 until May 2013, Ms. McCaw served in that role as a Consultant to the Company, and since May 2013, she has served in that role as an employee of the Company. Ms. McCaw has almost thirty years’ experience as both in-house and outside corporate counsel. She has expertise in advising executives and corporate Boards of Directors on complex legal matters; exercising sound judgment in partnering with executives to position the organization in the most favorable posture regarding its exposures and risks; directing the legal and contract negotiations for mergers, acquisitions, divestitures and other business initiatives; advising executives and Boards on the business and financial impacts of key strategic initiatives; and directing the Company’s defense of difficult legal challenges.
 

In 2008, Ms. McCaw formed her consulting practice, and through her practice she provides General Counsel guidance to various clients in the medical device industry and in the diagnostic, health and wellness sectors of the healthcare industry.
 

 From 1996 to 2008, Ms. McCaw served as counsel to Matria Healthcare, Inc., a publicly traded healthcare company serving the disease management, wellness, obstetrical clinical services and medical device design, development and manufacturing sectors of healthcare. Ms. McCaw served Matria Healthcare as Senior Vice President, General Counsel and Secretary from 2006 to 2008, as Vice President of Legal, General Counsel and Secretary from 1998 to 2006 and as Assistant General Counsel and Assistant Secretary from 1996 to 1998.
 

Prior to Matria, Ms. McCaw was a Partner in the Connecticut law firm of Tyler, Cooper & Alcorn from 1990 to 1996 and Associate in the firm from 1983 to 1990. While with the law firm, Ms. McCaw specialized in mergers and acquisitions, general corporate and healthcare law, representing a broad range of publicly held and private corporations.
 

Ms. McCaw earned a bachelor's degree in accounting from Miami University and Cleveland State University and her law degree from the University of Connecticut School of Law. Ms. McCaw is a Certified Public Account, licensed to practice in New York, and a member of the Connecticut, Georgia, and American Bar Associations.

 

Deborah Dean | Executive Vice President

In July 2012, Ms. Dean joined MiMedx in the capacity of Vice President of Operational Systems. In October 2012, Ms. Dean was appointed Executive Vice President of MiMedx.  Ms. Dean is an executive with C-Level expertise and experience in operations, general management, sales & marketing, business development, key account management, technology, data integration, analytics, applications development, informatics and technical infrastructure.  
 

Prior to joining MiMedx, Ms. Dean was President & Chief Operating Officer of HolaDoctor, the Number One Hispanic Health Digital Site and exclusive partner to Univision.com.  During her tenure with HolaDoctor, she played a key role in the transformation of the company from a primarily translation and research consulting company to a health information company delivering over 12 million digital impressions per month.
 

Immediately prior to her association with HolaDoctor, Ms. Dean served with Matria Healthcare from 2005 to 2008. She began her career with Matria in the capacity of Vice President of Information Technology with responsibility for all Technology applications development, database management and systems networking and infrastructure. In February 2008, she was appointed to the position of Executive Vice President and Chief Technology Officer for Matria Healthcare reporting directly to the Chairman & CEO. In this elevated role, she assumed the additional responsibilities for the Product Management and Informatics Departments where she led the massive data integration of all disparate health plan, employer, Pharmacy Benefit Manager, and Third Party Administration systems into the Company’s proprietary health wellness and disease management software.  With her 15 years of healthcare expertise, Ms. Dean brought a proven process and development discipline to Matria Healthcare’s Technology organization.  She engineered and enhanced the architecture for data processing infrastructure of this disease management and wellness company to become a core selling point and strength. Matria Healthcare was sold to Inverness Medical Innovations in May 2008 in a transaction valued at over $1.2 billion.
 

Prior to joining Matria, Ms. Dean was Senior Vice President of Research and Development and General Manager of the Provider Business for Quovadx, Inc., a leading healthcare integration company. While at Quovadx, she developed the premier eligibility and claims clearinghouse product that integrated the top clearinghouses such as HDX, WebMD, MedUnite, Proxymed and Medifax. Ms. Dean joined Quovadx via its acquisition of Healthcare.com (Healthdyne Information Enterprises) where she held key data warehousing and client informatics reporting management roles. Prior thereto, she served with Medstat (acquired by Thomson Reuters) in numerous data warehousing and informatics roles.
 

Ms. Dean earned a bachelor’s degree in Health Services Administration from Arkansas State University. 

 

Brent Miller | Executive Vice President

Mr. Miller joined MiMedx in June 2012 as the Company’s Vice President of Business Development. In October 2012, Mr. Miller was appointed Executive Vice President of the Company. He is an operating executive with over 30 years’ experience in healthcare sales, marketing and general management with a proven track record of increasing revenues and profits through organic growth and successful acquisitions. Prior to joining MiMedx, Mr. Miller was the General Manager for SureFit, a division of Hanger Orthopedic Group. Purchased by Hanger in 2007, SureFit provides the podiatric physician with a high quality, easy to use and cost effective solution to supplying their diabetic patients with therapeutic footwear.
 

Prior to serving at SureFit, Mr. Miller was EVP Sales & Marketing at Facet Technologies, LLC, a medical device company focused on design, development, and manufacturing for OEM clients such as Abbott, Bayer, BD, LifeScan (J&J), Roche, and Flextronics. Beginning in 1996, Mr. Miller served with Facet and its predecessor company, Gainor Medical, for over 10 years where he managed Gainor Medical’s U.S. Diabetes mail order supply company, Diabetes Self Care, prior to the purchase of Gainor Medical by Matria Healthcare.
 

Prior to joining Gainor Medical in 1995, Mr. Miller worked at Bayer Healthcare for over 13 years. During his career at Bayer, he progressed through positions in Financial Planning, International Product Management and Strategic Marketing. Prior to leaving Bayer, he was VP Alternate Care, with overall P&L responsibility for the US Diabetes and Urine Chemistry businesses headquartered in Tarrytown, NY.
 

Mr. Miller earned a Bachelor of Science degree and an MBA from Rensselaer Polytechnic Institute in Troy, NY.

 

Thornton Kuntz | Senior Vice President of Administration

In October 2009, Mr. Kuntz began his association with MiMedx Group, Inc. providing advisory services to the Company. In January 2010, his services were expanded to include serving MiMedx in the position of Vice President of Human Resources & Administration on a part-time basis. In April 2014, Mr. Kuntz was named Senior Vice President of Administration. Mr. Kuntz provides his services to MiMedx through his human resources advisory solutions business, Austin Consulting Group, LLC, in which he serves as its President/CEO.
 

Mr. Kuntz brings 35 years of C-level expertise in learning & development, safety management, talent management & acquisition, process design, change management, strategic planning,  organizational alignment, mergers & acquisitions, executive & Board compensation, corporate administration, succession planning, external/internal communications and public reporting. He has successfully led talent management processes and learning & development initiatives to strategically transition companies into dominant market leaders, facilitated organizational re-design to produce prolific growth, successfully assimilated more than 35 acquisitions, created “corporate university” curriculums to support aggressive initiatives for clinical, technology, operations, sales and general management, and led the succession and career planning initiatives for executive talent. During his career, Mr. Kuntz has received numerous awards for excellence in public company annual reports.
 

Mr. Kuntz served with Alere f/k/a Matria Healthcare, Inc. f/k/a Healthdyne, Inc. from 1992 until 2008. From 2008 to 2009, Mr. Kuntz served as Executive Vice President of Culture & Performance for Alere, a subsidiary of Inverness Medical Innovations, Inc. which acquired Matria Healthcare in 2008. Mr. Kuntz served Matria as Senior Vice President and Chief Administrative Officer from 2006 to 2008, as Vice President of Administration from 1998 until 2006, and as Vice President of Human Resources from the 1996 formation of Matria Healthcare (the merger of Healthdyne Maternity Management and Tokos Medical Corporation) until 1998. Mr. Kuntz joined Healthdyne, Inc., the predecessor company to Matria Healthcare , in 1992 and served as Vice President of Administration until the merger in 1996.
 

Prior to joining Healthdyne, Mr. Kuntz was associated with Glasrock Home Health Care, Inc. from 1985 to 1992, where he served as Vice President of Human Resources from 1989 to 1992 and as Director of Human Resources Administration from 1985 until 1989. Mr. Kuntz was associated with The Louisiana Land and Exploration Company from 1977 to 1985 in various human resources positions including Manager of Employee Relations from 1980 to 1985. Mr. Kuntz served as a Human Resources Representative with the Ocean Drilling and Exploration Co. from 1975 to 1977.
 

Mr. Kuntz earned a bachelor's degree in management from the University of New Orleans in 1975.

 

Michael W. Carlton | Senior Vice President of Global Sales

Mr. Carlton joined MiMedx Group in November 2009 as the Company’s Vice President of Global Sales. In January 2014, Mr. Carlton was named Senior Vice President of Global Sales. With over 20 years of domestic and international medical device sales and sales management experience, Mr. Carlton leads the Company’s initiatives to broadly and effectively market its products and tissues.
 

Mr. Carlton has established the sales and marketing infrastructure to serve the unique sales and marketing needs created by Company’s products and tissues that are in high demand.  He has assembled a direct sales force of highly seasoned sales professionals, regional management and national management with specialty and focus in the segments of advanced wound care, burns healing, soft tissue trauma, nerve and tendon repair, spinal applications, orthopedics and sports medicine. Complementing the direct sales force, Mr. Carlton has assembled and leads a specialized network of distributors and independent sales representatives.
 

Mr. Carlton’s most recent role prior to joining MiMedx Group was with Synthes Spine, where he was the Orthopedic Manager in Georgia. Prior to his role with Synthes Spine, Mr. Carlton was responsible for a national sales force with Abbott Vascular, a $600 million division of parent company, Abbott. He joined Abbott in 2000 and was responsible for all US commercial operations, marketing, and customer service with responsibility for 14 regions, and a sales force of 185 representatives.  During his tenure with Abbott, Mr. Carlton last served as the National Director of their $160 million Coronary and Vascular Closure Divisions.
 

Before joining Abbott Vascular, he served for six years in multiple sales, training and sales management roles at Boston Scientific. Prior to Boston Scientific, Mr. Carlton began his sales career with Kendall Urologic and Wound Care Products where he served for four years in key account sales positions.
 

Mr. Carlton is a graduate of Miami University, Oxford Ohio with a B.A. in Marketing and attended Xavier University, Keller School of Management, in Cincinnati, Ohio for course work toward an MBA.  

 

Marlene M. DeSimone | Senior Vice President of Corporate Strategic Development

Since joining MiMedx in November 2013, Ms. DeSimone has served as Senior Vice President of Corporate Strategic Development. She was instrumental in the development of the MiMedx Corporate Strategic Plan which defines the framework for the Company’s corporate growth over the next five years. Ms. DeSimone facilitated the collaboration among the Company’s executives and its Board of Directors to produce this important plan for the Company’s future growth.  In addition, Ms. DeSimone is responsible for providing executive leadership and management of the Company’s marketing organization to position MiMedx as the leader across the Company’s portfolio of products and various markets.
 

Immediately prior to joining MiMedx, Ms. DeSimone was a Managing Partner of Velocity P3, a specialized solutions consulting firm providing services to the healthcare industry. Ms. DeSimone was a co-founder of Velocity P3 which was focused on commercialization strategies, business/leadership acceleration, and patient adherence support. Prior to forming Velocity P3, Ms. DeSimone served with Matria Healthcare from 2004 through 2009.  She was the Senior Vice President of Business Development at Matria, and in that role, she built Matria’s biopharmaceutical business focused on patient adherence activities.  In addition, she led the sales organization for the employer and health plan verticals where revenues were in excess of $350 million.  Ms. DeSimone left Matria one year after its sale to Inverness to start Velocity P3.
 

Prior to Matria, Ms. DeSimone held various and increasingly more responsible, sales, marketing and new business development positions with leading biopharmaceutical companies.  With Dendrite International/SYNAVANT Inc., she served in the role of Vice President, Global Strategic Solutions; with DigitalDoctor.com, she held the position of Vice President, Business Development; and with Schering-Plough Corporation, she served as Product Director, Marketing for the BioOncology franchise, Oncology District Manager, National Account Manager, Sales Operations Manager and Sales Representative. Ms. DeSimone began her career as a Registered Nurse with George Washington University Medical Center before moving into medical sales with Bialek Corporation.
 

Ms. DeSimone earned her Bachelor of Science in Nursing from The American University in Washington, D.C. She is a Foundation Associate of the Women Business Leaders/U.S. Healthcare Industry Foundation, a member of the Healthcare Marketing & Communications Council and the Healthcare Businesswoman’s Association where she served on its Board of Directors from 2004-2006.

Donald E. Fetterolf, M.D., FACP | Chief Medical Officer

Dr. Fetterolf currently serves as Chief Medical Officer of MiMedx Group.  He began his association with MiMedx in July 2009. Initially, Dr. Fetterolf served as a consultant to the Company, and in June 2011, he increased his involvement with MiMedx in the role of part-time Vice President of Medical Affairs, and in October 2011, Dr. Fetterolf transitioned into his full time role of CMO. 
 

Dr. Fetterolf is an experienced physician executive with extensive expertise in clinical medicine, health care business administration, medical informatics and the management and economics of complex health care organizations. 
 

Before joining MiMedx, Dr. Fetterolf’s work experience included roles as Executive Vice President of Health Intelligence at Alere, Executive Vice President of Health Intelligence at Matria Healthcare, Chief Medical Officer of Highmark, Inc., President of the ALPHA Health Network in Pennsylvania, and President of Allegheny Intermed, a medical group practice.
 

These previous operating environments have included a major health plan, corporate disease management, medical practice, and hospital-physician joint venture (“PHO”) organizations.  He has also delivered private consulting services for commercial and government accounts. 
 

Dr Fetterolf was the first recipient of the Brian Hayes Award of the Blue Cross Blue Shield Association in 2004, created to honor the most outstanding medical director in the Blue Cross Blue Shield system.  He was awarded the DMAA 2006 Disease Management Leadership Annual Award for Outstanding Individual Leadership.  He was recognized in 2010 as a national thought leader by the Case Management Society of America (CMSA) in their Shining Lights edition of their journal.  He is a Fellow in the American College of Physicians, the College of Physicians of Philadelphia, the American College of Physician Executives, and the Academy of Healthcare Management.  Dr. Fetterolf is Past President of the American College of Medical Quality, where he is a Distinguished Fellow and is Secretary/Treasurer of the American Board of Medical Quality.  He has served in the past on the Board of Directors of the Disease Management Association of American (DMAA), where he also directed a national effort to develop economic measures in disease management.  He is on the editorial board of several journals including Population Health Management, the American Journal of Medical Quality, and Perspectives in Health Information Management.
 

Dr. Fetterolf received dual undergraduate degrees in Chemistry and Biochemistry and an M.D. degree from the University of Pennsylvania in Philadelphia.  He completed an internship and residency in internal medicine at the University of Pittsburgh, and there also completed a Masters in Business Administration.  Don is certified by the American Board of Internal Medicine, the American Board of Medical Quality and the American Board of Quality Assurance and Utilization Review Physicians.

 

Thomas J. Koob, PhD | Chief Scientific Officer

Dr. Koob is the Chief Scientific Officer of MiMedx. He is the senior executive responsible for the overall research direction and oversight of the Company’s product and tissue offerings. Dr. Koob is the inventor on the patents related to the Company’s CollaFix™ technology that are the basis of the Company's license agreement with Shriners Hospitals for Children and the University of South Florida. MiMedx was founded around the collagen technology developed by Dr. Koob.
 

Prior to MiMedx, Dr. Koob was Section Chief of Skeletal Biology at Shriners Hospital for Children in Tampa, Florida. During the fourteen years he held this position, Dr. Koob developed and patented the core technology for what would become the MiMedx CollaFix™ technology platform. Prior to his tenure with Shriners, Dr. Koob held various research appointments at institutions such as the Department of Biology at Boston University, Department of Biological Chemistry at Harvard Medical School, Department of Biology at the University of New Mexico, Department of Anatomy at the University of New Mexico School of Medicine, Orthopaedic Biomechanics Laboratory at Beth Israel Hospital, and Mount Desert Island Biological Laboratory.
 

Dr. Koob has published over 125 biomedical and biological articles and 12 book chapters, and he is listed as an inventor on over 40 issued and pending patents.
 

Dr. Koob received his Ph.D. in Biochemistry from Washington University School of Medicine in St. Louis, Missouri. He completed four years of post-doctoral training at Harvard Medical School and four years of specialty training in the Laboratory of Skeletal Disorders, Department of Orthopaedics at Children's Hospital Medical Center in Boston.

Frank Burrows | Vice President Clinical and Scientific Liaison

Mr. Burrows joined MiMedx Group in April 2011 as Vice President of Wound Care to lead the marketing of the Company’s wound care offerings and other exciting products and tissues. He assumed the role Of Vice President of Global Marketing in August 2011 to focus on expanding the Company’s presence in the regenerative tissue market. In October 2012, Mr. Burrows was appointed to the position of Vice President of Corporate Strategy. He has brought to MiMedx over 20 years of experience and expertise in developing and implementing sales and marketing plans that have created prolific growth for numerous medical devices and pharmaceuticals. In March 2014, Mr. Burrows was named Vice President of Clinical and Scientific Liaison.
 

Mr. Burrows has held positions with notable companies like Johnson & Johnson, Smith & Nephew, W.L. Gore and CryoLife.  In Mr. Burrow’s 20-year career, he has amassed a track record for successfully developing and implementing strategic and tactical marketing plans to launch and grow medical devices, human tissue, and pharmaceuticals in the areas of tissue engineering; regenerative medicine; wound closure and healing; growth factor therapy; cardiothoracic, vascular, endovascular surgery; diabetes; women’s health; anesthesia; heart disease; biologics; and bio-active therapeutics.
 

Mr. Burrows’ most recent role prior to joining MiMedx Group was with CryoLife, Inc., where he served as Director of Marketing and had responsibility for development and execution of marketing plans for allograft tissues for uses in aortic, pulmonary and vascular procedures. Before his tenure with CryoLife, he was Director of Sales & Marketing for Histogen Aesthetics, a startup biotechnology company in the regenerative medicine market. Prior thereto, he was Marketing Director for W.L. Gore from 2006 to 2008 and had responsibility for leading their global marketing efforts in the Abdominal, Aortic and Aneurysm (AAA) endovascular market segment.
 

From 2001 to 2006, Mr. Burrows served with J&J Wound Management Company, a division of ETHICON, as Director of Professional Education from 2004 to 2006 and as Sr. Product Director from 2001 to 2004. With J&J, he successfully revitalized and re-launched their brand in the highly differentiated and competitive advanced wound care market and directed their formal education programs to drive scientific and clinical utilization rationale. From 1999 to 2000, Mr. Burrows served as Vice President of Adient and directed its account teams serving key accounts such as Bristol-Myers Squibb and Ortho-McNeil. He served as Marketing Manager, Acute Care with Smith & Nephew from 1997 to 1999 focusing on their acute care products and supporting the launch of the Company’s novel biotechnology and advanced wound care products. In 1991, Mr. Burrows began his career with Advanced Tissue Sciences, where he held numerous marketing and business development roles.
 

Mr. Burrows holds degrees in Marketing from Point Loma Nazarene University and an MBA in Marketing & Advertising from University of La Verne. Mr. Burrows received his EMT from Saint Michael's Medical Center.

 

Rebeccah J. C. Brown, PhD | Vice President of Product Development, Regulatory Affairs, and Quality Assurance

Dr. Brown joined SpineMedica LLC, an early-stage predecessor company to MiMedx, in 2005. She initially served as the Director of Project Management and Senior Engineer for SpineMedica, and later served as its Director of Research and Development and as Vice President of Operations. In those roles, she was instrumental in the development and launch of the Company’s HydroFix® technology. Since the Company’s inception, Dr. Brown was been leading the Company’s product development efforts, including growing and managing the intellectual property portfolio. Following the combination of SpineMedica with MiMedx, Inc. in 2007, Dr. Brown has served as the Company’s senior executive responsible for Product Development. In April 2013, Dr. Brown was named Vice President of Product Development, Regulatory Affairs and Quality Assurance.
 

Dr. Brown has over twenty years of experience leading teams to produce innovative and impactful products.  She has worked at companies ranging in size from 12 employees to 120,000, and has an impressive track record for integrating customer needs with company goals. 
 

Before joining SpineMedica, Dr. Brown worked as Project Manager and Staff Engineer at SaluMedica, LLC, a medical device company pioneering the development of devices to replace soft tissue throughout the body. While a graduate student at the Georgia Institute of Technology where her research focused on the durability of orthopedic implants, Dr. Brown also worked with SaluMedica, as well as Oak Ridge National Laboratory and Advanced Tissue Sciences. Dr. Brown designed and fabricated mechanical testing systems to evaluate the durability of cartilage and cartilage prostheses.
 

Dr. Brown has also worked at Centerpulse (formerly Sulzer Medica) in Winterthur, Switzerland as a Research Engineer where she investigated xenograph amd tissue engineering options for articular cartilage repair and treatment. Before Centerpulse, Dr. Brown worked as a Product/Process Engineer at Hewlett-Packard.
 

Dr. Brown holds a Ph.D. and M.S. from the Georgia Institute of Technology, where she was a National Science Foundation Graduate Research Fellow, and a B.S. in Mechanical Engineering from the Massachusetts Institute of Technology.

 

Randall Spencer | Vice President of Clinical Innovation

Mr. Spencer is the co-founder of Surgical Biologics, a leading processor of amnion tissue for use in a variety of surgical implants. Since the founding of Surgical Biologics in 2006, he led the development of the proprietary PURION® Process, which processes human amniotic membrane to produce a safe, effective and minimally manipulated implant for homologous use. He has been a pioneer in the development of the latest advances in processing amniotic membrane tissue. MiMedx® acquired Surgical Biologics in January 2011, and Mr. Spencer served as the Company’s Director of Product Development until March 2013, when he assumed the role of Vice President of Clinical Innovation.
 

Mr. Spencer has been in the bioimplant industry since its infancy, with over 23 years of experience. He is an industry expert in the development of new products and new surgical treatments using bioimplant materials. Throughout his career, Mr. Spencer has made significant contributions to the development of a wide range of products which are now considered the standard of care for certain surgical procedures.
 

Before founding Surgical Biologics, he was Product Manager Bone Biopsy Division at InterV Medical Device Technologies. Prior to InterV, Mr. Spencer was Product Manager Regenerative Products at Tutogen Medical, where he designed products used in spinal and dental surgeries. Before joining Tutogen, he was with Regeneration Technologies, where Mr. Spencer created products that are used in spinal, sports medicine and orthopedic surgeries. Earlier in his career, Mr. Spencer worked for Johns Hopkins University as a researcher.
 

Mr. Spencer earned a Bachelors of Science degree in Health Science from Grand Valley State University.

 

Gary J. Stanziano, M.D. | Vice President of Medical Affairs

Dr. Stanziano joined MiMedx in September 2013, and currently serves in the capacity of Vice President of Medical Affairs.  In this role, Dr. Stanziano is the Company’s key clinical expert interfacing with Medicare Administrative Contractors (MACs), commercial health plans and state Medicaid programs to facilitate broader reimbursement for MiMedx products. Prior to joining MiMedx, Dr. Stanziano was associated with Matria Healthcare, the nation’s leading disease management, health and wellness, and maternity management provider.  

In his 20-year tenure at Matria, Dr. Stanziano played an instrumental role in establishing and sustaining Matria’s relationships with health plans.  With nearly 1,000 commercial health plan contracts managed by Dr. Stanziano while at Matria, he is one of the most knowledgeable Medical Directors in the reimbursement arena.  Dr. Stanziano initially joined Matria in the role of Vice President, Medical Affairs where he spent 11 years serving in that capacity. He later was appointed Senior Vice President of Women’s and Children’s Health, and spent two years in that role. In his last role with Matria, Dr. Stanziano served for seven years as Executive Vice President of Women’s and Children’s Health.  Prior to Matria, Dr. Stanzianio was Medical Director for Solvay Pharmaceuticals.

Dr. Stanziano has authored in excess of 55 manuscripts on clinical studies that have been published in peer-reviewed literature. Dr. Stanziano has over 125 clinical abstracts that have been published in peer-reviewed journals and/or presented by him at leading conferences and symposiums including the American Diabetes Association (ADA), American College of Obstetricians & Gynecologists (ACOG), Central Association of Obstetrician and Gynecologists (CACOG), Disease Management Association of America (DMAA), National Perinatal Association (NPA), Society for Gynecologic Investigation (SGI), and Society of Maternal-Fetal Medical (SMFM).

Dr. Stanziano received his M.D. from the Medical College of Georgia School of Medicine in Augusta, Georgia. He earned a BS degree in Biology and in Electrical Engineering from The Georgia Institute of Technology.

David H. Mason, Jr., M.D. | Vice President of Medical Affairs for Clinical Practice

Dr. Mason joined MiMedx in June 2014, in the position of Vice President of Medical Affairs for Clinical Programs.  Dr. Mason is a Board Certified Internist, board eligible in Rheumatology and Infectious Diseases, whose experience includes a 27-year pharmaceutical and medical device industry career, with increasing levels of responsibility.  His experience covers multiple therapeutic areas and includes management of Clinical Development and Medical Affairs groups; Regulatory Affairs including QA; Public Affairs, Public Policy and Public Relations.  Dr. Mason has extensive experience in all phases of drug development including preclinical, regulatory and clinical trials from Phases I through IV. His vast experience includes handling IND filings, protocol writing, more than ten successful BLA and NDA submissions, multiple successful 510(k) and de novo device clearances, and a similar number of drug and device product launches.

Before joining MiMedx, Dr. Mason previously served as Senior Vice President and Chief Medical Officer of Given Imaging where he led clinical trials, regulatory affairs and medical marketing initiatives. Before joining Given, Dr. Mason served with UCB Pharma as the company’s Vice President, Clinical Development and Global Head of Inflammation Clinical Research. In this role, Dr. Mason led the U.S. and U.K. teams in support of the regulatory pathways for the company’s portfolio of anti-inflammatory drugs. Dr. Mason also served with AVI BioPharma as its Senior Vice President of Clinical Development and Regulatory Affairs where he led drug development efforts including clinical programs in multiple therapeutic areas.

After medical school, Dr. Mason pursued a 15 year career in medical practice in both academic and private practice settings. During this time, Dr. Mason was a practicing physician in internal medicine, infectious diseases and rheumatology. Following his tenure in medical practice, Dr. Mason began his pharmaceutical and medical device industry career by joining Ciba-Geigy Pharmaceuticals in the capacity of Director, Clinical Research and Executive Director, Medical Affairs.

Dr. Mason has authored more than 15 manuscripts on clinical studies that have been published in peer-reviewed literature. He has authored a textbook article and a number of clinical abstracts that have been published in peer-reviewed journals.

Dr. Mason received his M.D. from Duke University Medical School. He earned a BA in Chemistry from Williams College. He completed an internship and fellowship in Rheumatology at Duke University Hospital and completed his residency in Internal Medicine at the University of Michigan Medical Center. Dr. Mason has also served as a Research Associate and USPHS SA Surgeon (Lt. Comm.) at NIH, NIAID, Laboratory of Viral Diseases, Bethesda, Maryland.

Conan S. Young, Ph.D. | Director of Research

Dr. Young joined the Research Department of MiMedx in May 2014 as Director of Research. He has responsibility for the Company’s laboratory based research and pre-clinical research. Dr. Young has extensive research experience in regenerative medicine, wound healing, vascular repair and orthopedics/sports medicine and serves the Company in leading its research initiatives in these and multiple other areas.

He served as Director of Research & Development with Shire Regenerative Medicine prior to joining MiMedx. At Shire, Dr. Young was instrumental in the company’s successful IND approval of its Dermagraft® product for new Phase III clinical programs in the U.S., Europe and Canada. Additionally, Dr. Young was instrumental in the initiation of Phase IIb clinical trials for the Shire Vascugel® therapy program. Before Shire, Dr. Young was with BioMimetic Therapeutics serving in various roles including the company’s Senior Scientist and its Director of Preclinical Biology. With BioMimetic, Dr. Young developed biologic/device combination products through Phase III clinical development.

Dr. Young began his career in regenerative medicine at the Harvard/Forsyth Institute where he last served as Staff Scientist and gained expertise in dental tissue engineering.

Dr. Young has authored 15 manuscripts on scientific studies that have been published in peer-reviewed literature. Dr. Young has over 45 abstracts and proceedings that have been published in peer-reviewed journals and/or presented by him at leading conferences and symposiums.

Dr. Young earned a B.Sc. in Cellular, Molecular, and Microbial Biology at the University of Calgary, he received a M.Sc. in Microbiology/Biotechnology from the University of Waterloo and was awarded a Ph.D. in Microbiology from the University of British Columbia.  He completed his Post-Doctoral work at Arizona State University, followed by a research/teaching position at the Harvard School of Dental Medicine.

Board of Directors

Parker H. "Pete" Petit | Chairman of the Board and Chief Executive Officer

Mr Petit joined MiMedx in February 2009 as the Company’s Chairman and Chief Executive Officer. A visionary healthcare executive, Petit has a history of developing companies from their emerging stages and leading them to maturity and significant stature in their respective markets.

In 1970, Mr. Petit founded Healthdyne, an international healthcare company that manufactured high technology healthcare devices, provided healthcare information systems and technology, and provided healthcare services and disease management. The Healthdyne related companies grew to annual revenues in excess of $1 billion.  In order to increase shareholder values, Healthdyne was split into several publicly traded companies through public offerings and spinouts to shareholders in 1995.  At that point, Mr. Petit relinquished the CEO role and remained Chairman of the Board of all the companies.  Subsequently, the home infusion therapy subsidiary was sold to W. R. Grace Corporation.  In 1995, Healthdyne Maternity Management was merged with Tokos Medical to form Matria Healthcare.  In 1997, Healthdyne Technologies was merged with Respironics. Mr. Petit resumed the duties of President and CEO of Matria Healthcare in 2000. In 2001, Healthcare.com, which was formerly Healthdyne Information Enterprises, merged with XCare.net Corporation to form Quovadx. Through Mr. Petit’s vision and leadership, Matria Healthcare transitioned into the industry’s only fully integrated health, productivity and disease management care continuum providing employer and health plan clients access to wellness programs, nurse triage services, decision support programs, disease management programs for chronic diseases, case management programs for acute and catastrophic conditions and unparalleled health data integration and informatics. Matria Healthcare was sold to Inverness Medical Innovations in May of 2008 in a transaction valued at over $1.2 billion.

Mr. Petit served on the Board of Directors of Atlantic Southeast Airlines for 16 years until it was acquired by Delta Airlines, and Norrell Corporation, which was acquired by Spherion Corporation. He currently serves on the Board of Trustees of the National Health Museum and is a member of the Board of Directors of Intelligent Systems Corporation. Mr. Petit currently serves as President of The Petit Group, an Investment Management Organization. Mr. Petit is a member of the Board of Directors of the Georgia Research Alliance, which is chartered by the state of Georgia to promote high technology and scientific development in the state, and he is a 1994 inductee into the Technology Hall of Fame of Georgia. 

Mr. Petit funded a professorial chair for “Engineering in Medicine” at Georgia Tech in 1986.  In 1995, he endowed the Petit Institute for Bioengineering and Biosciences at Georgia Tech.  In 2001, he helped fund the biotechnology building at Georgia Tech which has his name and in 2004 the Science Center building at Georgia State University which also has his name. In 2007, he was inducted into the Georgia State Business School Hall of Fame. In October of 2011, Mr. Petit was inducted into the National Academy of Engineering.

Mr. Petit received his bachelor’s degree in Mechanical Engineering and Master of Science degree in Engineering Mechanics from Georgia Tech. He received his MBA degree in Finance from Georgia State University in 1973.

Joseph G. Bleser

Mr. Bleser became a financial consultant serving public and private companies in the healthcare and technology industries in 1998 after serving for over 20 years as chief financial officer for several public companies in the healthcare and technology industries, including HBO & Company, Allegiant Physician Services, and Transcend Services, and Healthcare.com, a Matria Healthcare public subsidiary. Mr. Bleser is a member of the Board of Directors, the Audit Committee and the Corporate Governance Committee of Transcend Services [NASDAQ: TRCR]. In addition, Mr. Bleser serves on the Board of Directors of a privately held information technology solutions company. Mr. Bleser is a licensed certified public accountant with ten prior years of public accounting experience in an international public accounting firm.

J. Terry Dewberry

Mr. J. Terry Dewberry is a private investor with extensive experience at both the management and board levels in the healthcare industry. He most recently served as a director with Respironics, Inc. and Matria Healthcare, Inc., where he served as a member of various committees including the Audit and Compensation committees. In 2008 both Respironics and Matria Healthcare were sold to larger companies. He currently serves on the board of DrTango, Inc., a private company in the multicultural communications and health management industry. He served as a director, vice chairman, president and chief operating officer, executive vice president and chief financial officer of Healthdyne, Inc. from 1981 to 1996. He has extensive experience in corporate mergers and takeovers on both the buy and sell sides at sizes up to $5 billion.

Charles R. Evans

Charles R. Evans serves on our board of directors. Mr. Evans became a director of the company in September 2012. Mr. Evans has over 30 years of experience in the healthcare industry. He is currently President of the International Health Services Group, an organization he founded to support health services development in underserved areas of the world. He is also currently a senior advisor with Jackson Healthcare, a consortium of companies that provide physician and clinical staffing, anesthesia management and information technology solutions for hospitals, health systems and physician groups. In addition, Mr. Evans is a fellow in the American College of Healthcare Executives, having previously served as governor of the college from 2004 to 2007 and as Chairman from 2008 to 2011. Previously, Mr. Evans was a senior officer with Healthcare Corporation of America (HCA) and managed various HCA divisions. Mr. Evans currently serves on the Board of Directors of Jackson Healthcare and CareSpot Express Healthcare. Additionally, Mr. Evans serves on the boards of non-profit organizations including MedShare International and MedicalMissions.org, and he is Chairman of the Hospital Charitable Service Awards.

Bruce L. Hack

Mr. Hack was Vice Chairman of the Board and Chief Corporate Officer of Activision Blizzard until 2009. Prior to that, Mr. Hack was Chief Executive Officer of Vivendi Games, from 2004 to 2008, Vice Chairman of the Board, Universal Music Group, from 1998 to 2001, and Chief Financial Officer, Universal Studios, from 1995 to 1998. From 1982-1994, Mr. Hack held several positions at The Seagram Company, including: Assistant to the Executive Vice President, Sales and Marketing, for Seagram USA; Director, Strategic Planning, at The Seagram Company Ltd.; and Chief Financial Officer of Tropicana Products, Inc. Prior thereto, he was a trade negotiator for the U.S. Treasury. He has been director of iSuppli Corporation since September 2007. Mr. Hack earned a B.A. in government at Cornell University and an M.B.A. in finance at the University of Chicago.

Charles E. Koob

Mr. Koob joined the law firm of Simpson Thacher & Bartlett, LLP in 1970 and became a partner in 1977. He retired from that firm on January 1, 2007 but remains of counsel. While at that firm, Mr. Koob was the co-head of the Litigation Department and served on the firm's executive committee. Mr. Koob specializes in competition, trade regulation and antitrust issues. Throughout his 37-year tenure, he has represented clients before the Federal Trade Commission, the Antitrust Division of the Department of Justice, and numerous state and foreign competition authorities. His resume includes the representation of Virgin Atlantic Airways, Archer Daniels Midland, and Kohlberg Kravis Roberts and Co. He received his B.A. from Rockhurst College in 1966 and his J.D. from Stanford Law School in 1969. In addition to his practice, Mr. Koob is trustee of the Natural Resources Defense Council, is president of the Yellowstone Park Foundation and is the co-chair of the Steering Committee for the current campaign for Stanford Law School. Mr. Koob is the brother of Dr. Thomas J. Koob, Chief Scientific Officer of MiMedx Group.

Larry W. Papasan

From July 1991 until his retirement in May 2002, Mr. Papasan served as President of Smith & Nephew Orthopaedics. He has been a director and chairman of the Board of Directors of BioMimetic Therapeutics [NasdaqGM:BMTI] since August 2005. BioMimetic Therapeutics, Inc. is developing and commercializing bio-active recombinant protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, periodontal, spine and sports injury applications. Mr. Papasan has also served as a member of the Board of Directors of Reaves Utility Income Fund [NasdaqCM:UTG], a closed-end management investment company, since February 2003 and of Triumph Bankshares, Inc. (a bank holding company) since April 2005. Mr. Papasan also serves as a director of SSR Engineering, Inc. and AxioMed Spine Corporation.

William C. Taylor

Mr. Taylor is an operating executive with over 20 years experience in healthcare product design, development and manufacturing. From 2001 through 2006, Mr. Taylor was President of Facet Technologies, LLC, a Matria Healthcare subsidiary. Facet was a medical device company focused on medical device design, development, and manufacturing for OEM clients such as Abbott, Bayer, BD, LifeScan (J&J), Roche, and Flextronics. Over his 14 year career at Facet and its predecessor company, he held various management positions, beginning with R&D, QA & Regulatory Affairs and progressing through general management. Mr. Taylor was instrumental in growing the design and manufacturing business from $14 million in revenue up to over $40 million, when the company was sold to Matria Healthcare. As president, he led the company to the number one market position in microsampling and grew it to over $85 million in revenue. He also led the company as CEO for 18 months after it was sold to a private equity company. A graduate of Purdue University, Mr. Taylor holds a bachelor of science degree in mechanical engineering and is co-inventor on eight patents. Mr. Taylor also serves on the board of directors.

Neil S. Yeston, M.D.

Neil S. Yeston, M.D. serves on our board of directors. Dr. Yeston became a director of the company in September 2012. Dr. Yeston currently serves as Active Senior Staff, Department of Surgery at Hartford Hospital. During his association with Hartford Hospital, Dr. Yeston previously served in various roles including Vice President of Academic Affairs, Director of Corporate Compliance, Vice President of Quality Management and Director of the Section on Critical Care Medicine, Department of Surgery. Dr. Yeston has formerly served as Professor of Surgery at the University of Connecticut and the Assistant Dean, Medical Education at the University of Connecticut School of Medicine. Prior to his associations with Hartford Hospital and the University of Connecticut, Dr. Yeston served with Boston University Medical Center in various positions including the Vice Chairman, Department of Surgery; Associate Professor of Anesthesiology; Director Progressive Care Unit; and Associate Professors of Surgery.

Quotations

“With the addition of the Purion® processed human amniotic membrane allografts, MiMedx® has exciting products to offer to physicians and our distribution networks. There are many potential applications for the AmnioFix® and EpiFix® tissue technologies for soft tissue repair and wound healing.”
-Parker H."Pete" Petit, Chairman of the Board and CEO

“MiMedx is committed to the commercialization of biomaterials that improve surgical outcomes by solving an unmet or underserved clinical need.”
-Randall Spencer, VP of Clinical Innovation & Founder

 

Healing Gifts

Healing-Gifts

The MiMedx® Placenta Donation Program, Give the Gift of Healing, provides an opportunity for mothers delivering full-term Caesarean section births to donate their placenta (often referred to as “afterbirth”) for medical uses. The placenta is normally discarded as medical waste. However, through donation, the family can provide a priceless gift of healing to those in need. This generous gift creates a personal legacy for the family and newborn knowing that they are helping individuals who require treatment for their difficult-to-heal wounds such as diabetic foot ulcers, venous leg ulcers and burns, or soft tissue injuries, and even those undergoing spine, eye and oral surgeries.

MiMedx® is honored to be entrusted with the precious gifts donated to us by the mothers participating in Give the Gift of Healing.  The placenta and its amnion/chorion membranes are rich in many elements that can be vital to healing numerous medical conditions.  MiMedx® has developed the special PURION® Process technology that preserves the properties that are crucial to the healing process, and through our technology, we produce allografts with remarkable healing capabilities. The allografts derived from the placentas entrusted to our care, have helped patients in countless medical applications in the wound care, surgical, sports medicine, ophthalmic and dental sectors of healthcare.

In recognition of the placental donations we are privileged to receive, we have formed our philanthropic mission and developed The MiMedx® Healing Gifts Program. Through Healing GiftsMiMedx® engages in noteworthy philanthropic endeavors ranging from eye surgeries in Guatemala to programs treating disadvantaged patients across the United States. We are proud of the impact Healing Gifts has made for many patients.

MiMedx® is committed to expanding the reach of Healing Gifts to thousands upon thousands of less fortunate patients. Our goal is to make our PURION® processed tissues available to serve the medical needs of the widest possible group of patients who can benefit from the healing generated by the tissues we process. To this end, the Company continues to actively pursue partnerships with philanthropic and non-profit programs. We pledge to be generous in our sharing of our resources and talents to serve the unmet needs of underserved patients.

We look forward to developing future Healing Gifts partnerships with the desire to affect different patient populations through monetary, product, and/or human resource based contributions.

 

"This video is one example of the impact that we are proud to be a part of. This program, Guatemala: A mission to restore sight, sponsored by IOP Ophthalmics provides vision restoring surgeries to the needy in Guatemala. The MiMedx® PURION® processed tissue is a preferred tissue because of its anti-inflammatory and scar reduction properties while enhancing the healing of the soft tissue."